Biohaven Pharmaceutical Holding Company Ltd. NYSE:BHVN

Biohaven Pharmaceutical Holding Company Ltd. stock price today

$15.49
-21.16
-57.75%
Financial Health
0
1
2
3
4
5
6
7
8
9

Biohaven Pharmaceutical Holding Company Ltd. stock price monthly change

-3.75%
month

Biohaven Pharmaceutical Holding Company Ltd. stock price quarterly change

-3.75%
quarter

Biohaven Pharmaceutical Holding Company Ltd. stock price yearly change

-16.23%
year

Biohaven Pharmaceutical Holding Company Ltd. key metrics

Market Cap
3.61B
Enterprise value
613.08M
P/E
-1.1
EV/Sales
2.85
EV/EBITDA
-0.84
Price/Sales
3.66
Price/Book
1.46
PEG ratio
N/A
EPS
-6.83
Revenue
N/A
EBITDA
-537.78M
Income
-517.18M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-356.25%
Oper. margin
-291.12%
Gross margin
83.38%
EBIT margin
-291.12%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Biohaven Pharmaceutical Holding Company Ltd. stock price history

Biohaven Pharmaceutical Holding Company Ltd. stock forecast

Biohaven Pharmaceutical Holding Company Ltd. financial statements

Average Price Target
Last Year

$60.6

Potential upside: 291.22%

Based on estimate of 8 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Profit margin
Jun 2023 0 -90.34M
Sep 2023 0 -102.57M
Dec 2023 0 -144.75M
Mar 2024 0 -179.50M
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Earnings per share (EPS)
2022-11-09 -1.30883 -1.75
2022-12-31 -7.11094 -3.78153
2023-03-23 -9.04966 -3.32
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Debt to assets
Jun 2023 506736000 119.48M 23.58%
Sep 2023 382736000 92.73M 24.23%
Dec 2023 513212000 85.23M 16.61%
Mar 2024 418532000 117.08M 27.98%
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Cash Flow
Jun 2023 -44.39M 76.25M -20.33M
Sep 2023 -94.81M 58.54M -39.65M
Dec 2023 -114.88M -3.91M 210.05M
Mar 2024 -102.63M 34.03M 3.42M

Biohaven Pharmaceutical Holding Company Ltd. alternative data

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Employee count
Aug 2023 928
Sep 2023 928
Oct 2023 928
Nov 2023 928
Dec 2023 928
Jan 2024 202
Feb 2024 202
Mar 2024 239
Apr 2024 239
May 2024 239
Jun 2024 239
Jul 2024 239

Biohaven Pharmaceutical Holding Company Ltd. other data

98.17% +3.32%
of BHVN is owned by hedge funds
63.49M +1.47M
shares is hold by hedge funds

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Insider trades (number of shares)
Period Buy Sel
Aug 2023 150000 0
Oct 2023 949634 0
Dec 2023 0 11000
Apr 2024 391355 0
May 2024 71500 0
Jun 2024 30000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CAR BRUCE officer: Chief Sc.. Common Shares 30,000 $33.58 $1,007,490
Purchase
CHILDS JOHN W director
Common Shares 28,000 $35.58 $996,240
Purchase
CHILDS JOHN W director
Common Shares 28,500 $35.17 $1,002,459
Purchase
BAILEY GREGORY director
Common Shares 15,000 $34.19 $512,880
Purchase
BAILEY GREGORY director
Common Shares 25,503 $39.18 $999,182
Purchase
BAILEY GREGORY director
Common Shares 48,780 $41 $1,999,980
Purchase
CHILDS JOHN W director
Common Shares 97,560 $41 $3,999,960
Purchase
CHILDS JOHN W director
Common Shares 73,170 $41 $2,999,970
Purchase
CHILDS JOHN W director
Common Shares 24,391 $41 $1,000,031
Purchase
CORIC VLAD director, officer: Chief Execut..
Common Shares 121,951 $41 $4,999,991
Patent
Grant
Filling date: 23 Nov 2020 Issue date: 13 Sep 2022
Application
Filling date: 10 Apr 2020 Issue date: 11 Aug 2022
Grant
Filling date: 19 May 2017 Issue date: 2 Aug 2022
Application
Filling date: 26 May 2019 Issue date: 14 Jul 2022
Grant
Filling date: 22 Nov 2017 Issue date: 14 Jun 2022
Application
Filling date: 10 Oct 2019 Issue date: 23 Dec 2021
Application
Filling date: 19 Jan 2020 Issue date: 4 Nov 2021
Grant
Filling date: 27 May 2020 Issue date: 10 Aug 2021
Application
Filling date: 17 Feb 2021 Issue date: 1 Jul 2021
Application
Filling date: 23 Nov 2020 Issue date: 18 Mar 2021
Insider Compensation
Dr. Vladimir Coric M.D. (1971) Chairman, Chief Executive Officer & Pres
$1,260,000
Mr. William Jones M.B.A. (1964) Chief Commercial Officer of Migraine & Common Diseases
$931,820
Dr. Elyse Stock M.D. (1958) Chief Medical Officer $726,790
Ms. Kimberly Gentile (1966) Senior Vice President of Clinical Operations $654,990
Tuesday, 17 December 2024
benzinga.com
Monday, 16 December 2024
prnewswire.com
Friday, 6 December 2024
prnewswire.com
Friday, 29 November 2024
seekingalpha.com
Monday, 25 November 2024
benzinga.com
benzinga.com
reuters.com
prnewswire.com
Tuesday, 12 November 2024
prnewswire.com
Wednesday, 2 October 2024
prnewswire.com
Tuesday, 1 October 2024
prnewswire.com
Monday, 30 September 2024
prnewswire.com
prnewswire.com
Tuesday, 24 September 2024
zacks.com
marketbeat.com
Monday, 23 September 2024
youtube.com
seekingalpha.com
investopedia.com
benzinga.com
marketwatch.com
investors.com
reuters.com
prnewswire.com
Friday, 20 September 2024
prnewswire.com
Thursday, 8 August 2024
prnewswire.com
Friday, 26 July 2024
seekingalpha.com
Friday, 28 June 2024
investorplace.com
Wednesday, 29 May 2024
investors.com
prnewswire.com
prnewswire.com
  • What's the price of Biohaven Pharmaceutical Holding Company Ltd. stock today?

    One share of Biohaven Pharmaceutical Holding Company Ltd. stock can currently be purchased for approximately $15.49.

  • When is Biohaven Pharmaceutical Holding Company Ltd.'s next earnings date?

    Unfortunately, Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) next earnings date is currently unknown.

  • Does Biohaven Pharmaceutical Holding Company Ltd. pay dividends?

    No, Biohaven Pharmaceutical Holding Company Ltd. does not pay dividends.

  • How much money does Biohaven Pharmaceutical Holding Company Ltd. make?

    Biohaven Pharmaceutical Holding Company Ltd. has a market capitalization of 3.61B. Biohaven Pharmaceutical Holding Company Ltd. made a loss 408.17M US dollars in net income (profit) last year or -$3.32 on an earnings per share basis.

  • What is Biohaven Pharmaceutical Holding Company Ltd.'s stock symbol?

    Biohaven Pharmaceutical Holding Company Ltd. is traded on the NYSE under the ticker symbol "BHVN".

  • What is Biohaven Pharmaceutical Holding Company Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Biohaven Pharmaceutical Holding Company Ltd.?

    Shares of Biohaven Pharmaceutical Holding Company Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Biohaven Pharmaceutical Holding Company Ltd.'s key executives?

    Biohaven Pharmaceutical Holding Company Ltd.'s management team includes the following people:

    • Dr. Vladimir Coric M.D. Chairman, Chief Executive Officer & Pres(age: 54, pay: $1,260,000)
    • Mr. William Jones M.B.A. Chief Commercial Officer of Migraine & Common Diseases(age: 61, pay: $931,820)
    • Dr. Elyse Stock M.D. Chief Medical Officer(age: 67, pay: $726,790)
    • Ms. Kimberly Gentile Senior Vice President of Clinical Operations(age: 59, pay: $654,990)
  • How many employees does Biohaven Pharmaceutical Holding Company Ltd. have?

    As Jul 2024, Biohaven Pharmaceutical Holding Company Ltd. employs 239 workers.

  • When Biohaven Pharmaceutical Holding Company Ltd. went public?

    Biohaven Pharmaceutical Holding Company Ltd. is publicly traded company for more then 2 years since IPO on 23 Sep 2022.

  • What is Biohaven Pharmaceutical Holding Company Ltd.'s official website?

    The official website for Biohaven Pharmaceutical Holding Company Ltd. is biohavenpharma.com.

  • Where are Biohaven Pharmaceutical Holding Company Ltd.'s headquarters?

    Biohaven Pharmaceutical Holding Company Ltd. is headquartered at 215 Church Street, New Haven, CT.

  • How can i contact Biohaven Pharmaceutical Holding Company Ltd.?

    Biohaven Pharmaceutical Holding Company Ltd.'s mailing address is 215 Church Street, New Haven, CT and company can be reached via phone at +20 3 4040410.

  • What is Biohaven Pharmaceutical Holding Company Ltd. stock forecast & price target?

    Based on 8 Wall Street analysts` predicted price targets for Biohaven Pharmaceutical Holding Company Ltd. in the last 12 months, the avarage price target is $60.6. The average price target represents a 291.22% change from the last price of $15.49.

Biohaven Pharmaceutical Holding Company Ltd. company profile:

Biohaven Pharmaceutical Holding Company Ltd.

biohavenpharma.com
Exchange:

NYSE

Full time employees:

239

Industry:

Biotechnology

Sector:

Healthcare

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

215 Church Street
New Haven, CT 06510

CIK: 0001689813
ISIN: VGG1110E1079
CUSIP: G11196105